European Archives - Page 1071 of 1158 - European Medical Journal

EMJ

Sniffing and Gasping Can Prevent Fainting

Vienna, Austria – 17 October 2015: Sniffing and gasping can prevent fainting, reveals research presented today at Acute Cardiovascular Care 2015…

EMJ

Exercise Does the Heart Good, Especially in Patients with Type 2 Diabetes

HIGH intensity intermittent exercise training has been shown to reverse heart abnormalities, improve heart structure, and benefit diabetes control…

EMJ

Novel Transplant Technique Frees Type 1 Diabetes Patient from Insulin Therapy

‘Cured!’ may be the statement on the lips of Type 1 diabetes patients in the next few decades, following a recent announcement by the…

EMJ

Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx)

At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses…

EMJ

Immunotherapy: Targeting tumour heterogeneity

At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research…

EMJ

Pacemakers Identify Atrial Fibrillation and Enable Initiation of Stroke Prevention

Vienna, Austria – 17 October 2015: Pacemakers identify atrial fibrillation and enable initiation of anticoagulation to prevent strokes, according to…

EMJ

Childhood Infections Associated with Increased Risk of Early Heart Attack

Vienna, Austria – 17 October 2015: Infections in childhood are associated with an increased risk of early heart attacks, according to research presented…

Treatment of Hypertension in New Frontiers

This symposium provided an excellent forum to discuss the global burden of hypertension, its challenges and approaches to best management.

New Paradigms in Heart Failure: RAAS Inhibition and the Management of Hyperkalaemia

This educational symposium discussed advances in blocking the renin–angiotensin–aldosterone system (RAAS) for patients with chronic systolic heart failure..

International, Large-Scale, Real-World Clinical Data Confirm the Safety Profile of Rivaroxaban

Rivaroxaban is a direct factor Xa inhibitor and a non-vitamin K antagonist (VKA) novel oral anticoagulant (NOAC) approved for a number of indications.